Wenpeng Zhao

机构：Shenyang Pharmaceutical University, Nanchang University, Henan University of Science and Technology, Xiamen University, First Affiliated Hospital of Xiamen University, First Affiliated Hospital of Jiangxi Medical College, Second Affiliated Hospital of Nanchang University · ORCID：0009-0006-8811-8418

发表论文 68 篇 · 总被引 1139 次 · h-index 20

代表论文

• The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest (2023 · Cell Death and Disease · 被引 83)
• The proto-oncogene tyrosine kinase c-SRC facilitates glioblastoma progression by remodeling fatty acid synthesis (2024 · Nature Communications · 被引 21)
• Low-dose Interleukin-2 For Psoriasis Therapy Based on the Regulation of Th17/Treg Cell Balance in Peripheral Blood (2023 · Inflammation · 被引 19)
• Modulating the elasticity of milk exosome-based hybrid vesicles to optimize transepithelial transport and enhance oral peptide delivery (2025 · Journal of Controlled Release · 被引 18)
• CD2AP promotes the progression of glioblastoma multiforme via TRIM5-mediated NF-kB signaling (2024 · Cell Death and Disease · 被引 18)
• The combination of temozolomide and perifosine synergistically inhibit glioblastoma by impeding DNA repair and inducing apoptosis (2024 · Cell Death Discovery · 被引 14)